AR015759A1 - HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS - Google Patents

HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS

Info

Publication number
AR015759A1
AR015759A1 ARP990101636A ARP990101636A AR015759A1 AR 015759 A1 AR015759 A1 AR 015759A1 AR P990101636 A ARP990101636 A AR P990101636A AR P990101636 A ARP990101636 A AR P990101636A AR 015759 A1 AR015759 A1 AR 015759A1
Authority
AR
Argentina
Prior art keywords
aryl
alkoxy
amino
group
carboxyl
Prior art date
Application number
ARP990101636A
Other languages
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR015759A1 publication Critical patent/AR015759A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente se relaciona con una clase de compuestos representados por la formula (I) donde el grupo (II) es un anillo heterocíclico monocíclico de 5-8miembros, insaturado optativamente que contiene de 1 a 4 heteroátomos, seleccionados del grupo formado por O, N o S, donde X1 se selecciona del grupo formadopor CH, CH2, N, NH, O y S; A es la formula (III) donde Y1 se selecciona del grupo formado por N-R2, O, y S; R2 se selecciona del grupo formado por H, alquilo,arilo, hidroxi, alcoxi, ciano, nitro, amino, alquenilo, alquinilo, amida, alquilcarbonilo, arilcarbonilo, alcoxicarbonilo, ariloxicarbonilo,haloalquilcarbonilo, haloalcoxicarbonilo, alquiltiocarbonilo, ariltiocarbonilo, aciloximetoxicarbonilo, alquilo sustituido optativamente con unoo mássustituyentes seleccionados entre alquilo inferior, halogeno, hidroxilo, haloalquilo, ciano, nitro, carboxilo, amino, alcoxi, arilo o arilo sustituidooptativamente con uno o más grupos halogeno, haloalquilo, alquilo inferior, alcoxi, ciano, alquilsulfonilo, alquiltio, nitro, carboxilo, amino, hidroxilo,ácido sulfonico, sulfonamida, arilo, arilo fusionado, heterociclos monocíclicos o heterociclos monocíclicos fusionados, arilo sustituido optativamente con unoo más sustituyentes seleccionados entre grupos halogeno, haloalquilo, hidroxi, alquilo inferior, alcoxi, metilendioxi, etilendioxi, ciano, nitro, alquiltio,alquilsulfonilo, ácido sulfonico, sulfonamida, derivados de carboxilo, amino, arilo, arilo fusionado, heterociclos monocíclicos y heterociclos monocíclicosfusionados, heterociclos monocíclicos y heterociclos monocíclicos sustituidos optativamente con uno o más sustituyentes seleccionados entre grupos halogeno,haloalquilo, alquilo inferior, alcoxi, amino, nitro, hidroxi, derivados de carboxilo, ciano, alquiltio, alquilsulfonilo, ácido sulfonico, sulfonamida, arilo oarilo fusionado; o R2 tomado junto con R7, forma un dinitrogeno de 4-12 miembros que contiene heterociclo sustituido optativamente con uno o más sustituyentesseleccionados del grupo formado por alquilo inferior, tioalquilo, alquilamino, hidroxi, ceto, alcoxi, halo, fenilo, amino, carboxilo o carboxiléster y feniloThis is related to a class of compounds represented by formula (I) where group (II) is a 5-8-member monocyclic heterocyclic ring, optionally unsaturated containing 1 to 4 heteroatoms, selected from the group consisting of O, N or S, where X1 is selected from the group consisting of CH, CH2, N, NH, O and S; A is the formula (III) where Y1 is selected from the group consisting of N-R2, O, and S; R2 is selected from the group consisting of H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxytoxycarbonyl, acyloxytoxycarbonyl, acyloxymethyl with one or more substituents selected from lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl, amino, alkoxy, aryl or aryl optionally substituted with one or more halogen, haloalkyl, lower alkyl, alkoxy, cyano, alkylsulfonyl, alkylthio, nitro groups, carboxyl, amino, hydroxyl, sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic heterocycles or fused monocyclic heterocycles, aryl optionally substituted with one or more substituents selected from halogen, haloalkyl, hydroxy, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano groups nitro, alkylthio, alkylsulfonyl, sulfonic acid, su lfonamide, carboxyl, amino, aryl, fused aryl, monocyclic and fused monocyclic heterocycles, monocyclic heterocycles and monocyclic heterocycles optionally substituted with one or more substituents selected from halogen, haloalkyl, lower alkyl, alkoxy, amino, nitro, hydroxy groups of carboxyl, cyano, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, fused aryl oaryl; or R2 taken together with R7, forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituents selected from the group consisting of lower alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl, amino, carboxyl or carboxylester and phenyl

ARP990101636A 1998-04-10 1999-04-09 HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS AR015759A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
AR015759A1 true AR015759A1 (en) 2001-05-16

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101636A AR015759A1 (en) 1998-04-10 1999-04-09 HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS

Country Status (17)

Country Link
EP (1) EP1070060A1 (en)
JP (1) JP2002511462A (en)
KR (1) KR20010042614A (en)
CN (1) CN1304406A (en)
AR (1) AR015759A1 (en)
AU (1) AU765294B2 (en)
BR (1) BR9910119A (en)
CA (1) CA2326665A1 (en)
CZ (1) CZ20003672A3 (en)
IL (1) IL138677A0 (en)
MY (1) MY133473A (en)
NO (1) NO20005084L (en)
NZ (1) NZ507292A (en)
PL (1) PL343406A1 (en)
RU (1) RU2215746C2 (en)
TW (1) TWI247008B (en)
WO (1) WO1999052896A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
DE69930764D1 (en) * 1998-12-23 2006-05-18 G D Searle Llc St Louis USE OF CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION TREATMENT OF NEOPLASIA
JP2002536411A (en) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー Lactam inhibitors of factor Xa and methods
EE200100528A (en) 1999-04-12 2003-02-17 Aventis Pharma Limited Substituted bicyclic heteroaryl compound, pharmaceutical composition containing it and their therapeutic use
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
SK15342001A3 (en) * 1999-04-28 2002-06-04 Basf Aktiengesellschaft Integrin receptor antagonists
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
ATE375330T1 (en) 2000-04-17 2007-10-15 Ucb Pharma Sa ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6720315B2 (en) 2000-06-15 2004-04-13 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
DE10204789A1 (en) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitors of the integrin alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
JP2006514050A (en) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション R isomers of β-amino acid compounds as integrin receptor antagonist derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2008313733A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh CGRP antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
JP5385297B2 (en) 2007-11-22 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New compounds
EP2225237A2 (en) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organic compounds
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2875021B1 (en) 2012-07-18 2017-08-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
MX2016015467A (en) 2014-05-30 2017-03-23 Pfizer Carbonitrile derivatives as selective androgen receptor modulators.
KR20180107121A (en) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 Meta-azacyclic aminobenzoic acid derivatives as pan integrin antagonists
HUE053620T2 (en) * 2016-11-08 2021-07-28 Bristol Myers Squibb Co Pyrrole amides as alpha v integrin inhibitors
CA3182964A1 (en) 2020-05-14 2021-11-18 Ube Corporation 1,4,5,6-tetrahydropyrimidin-2-amine derivative
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (en) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 Pharmaceutical composition for providing treatment for or preventing alport syndrome
CN115626912B (en) * 2022-09-27 2024-03-26 中山大学 Thiourea compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
RO118290B1 (en) * 1995-08-30 2003-04-30 Gdsearle & Co Phenyl carbonyl urea derivatives and pharmaceutical composition
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
CA2263999A1 (en) * 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
WO1999052896A1 (en) 1999-10-21
TWI247008B (en) 2006-01-11
CA2326665A1 (en) 1999-10-21
JP2002511462A (en) 2002-04-16
NZ507292A (en) 2003-12-19
CZ20003672A3 (en) 2001-08-15
MY133473A (en) 2007-11-30
PL343406A1 (en) 2001-08-13
CN1304406A (en) 2001-07-18
EP1070060A1 (en) 2001-01-24
BR9910119A (en) 2001-10-09
AU3449999A (en) 1999-11-01
NO20005084L (en) 2000-11-27
NO20005084D0 (en) 2000-10-09
RU2215746C2 (en) 2003-11-10
KR20010042614A (en) 2001-05-25
AU765294B2 (en) 2003-09-11
IL138677A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
AR015759A1 (en) HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS
ECSP941085A (en) DERIVATIVES OF AMIDA, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
EA200600257A1 (en) DERIVATIVES OF TRIAZOLOPYRIMIDINE AS KINASE GLYCOGENSINTAZY-3 KINASE INHIBITORS
MX368680B (en) Animal pest control method.
AR038863A1 (en) USE OF A GARFT AND / OR AICARFT INHIBITOR AND AN ANTITOXIC AGENT TO PREPARE A DRUG TO SELECTLY DESTROY MTAP-DEFICIENT CELLS FROM A MAMMER
AR055360A1 (en) MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
RU2000128033A (en) Heterocyclic derivatives of glycyl-beta-alanine as vitronectin antagonists
PE20021005A1 (en) QUINAZOLINES AS INHIBITORS OF MMP-13
SE8303208D0 (en) Heterocyclic Associations
PE20050265A1 (en) DERIVATIVES OF ALKYLARYL ACID AS INHIBITORS OF DIACILGLICEROL ACYLTRANSFERASE TYPE 1 (DGAT-1)
NO20013254D0 (en) New Diphenylurea Compounds, Methods of their Preparation and Pharmaceutical Compositions Containing Them
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
MX2010000658A (en) Pyrimidine derivatives 934.
ATE491704T1 (en) 4-Ä2-(CYCLOALKYLAMINO)PYRIMIDINE-4-YLÜ-(PHENYL)IMIDAZOLINE-2-ONE DERIVATIVES AS INHIBITORS OF P38 MAP KINASE FOR THE TREATMENT OF INFLAMMATORY DISEASES
AR068376A1 (en) USEFUL HETEROCICLIC AMIDAS TO INHIBIT THE VIA HEDGEHOG.
DK435583A (en) PROCEDURE FOR THE PREPARATION OF HETEROCYCLIC DERIVATIVES OF CYCLOBUTAN
CO4970811A1 (en) PHARMACEUTICAL COMPOUNDS INHIBITORS OF ATPase SENSITIVE TO BAPHILOMYCIN AND PREPARATION PROCESS
AR038842A1 (en) ANTIPARASITARIAN ARTEMISININE DERIVATIVES (ENDOPEROXIDS)
AR017097A1 (en) COMPOUNDS OF 2- (3H) -OXAZOLONA, USEFUL AS SELECTIVE COX-2 INHIBITORS; PROCEDURE TO PREPARE SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FORMED WITH SUCH COMPOUNDS
ES500810A0 (en) AMINOALCOXIPIRAZOLES PREPARATION PROCEDURE
EA201070197A1 (en) DERIVATIVES 1-OXO-IZOINDOLIN-4-CARBOXAMIDES AND 1-OXO-1,2,3,4-TETRAHYDRO-ISOHINOLIN-5-CARBOXAMIDES, METHOD FOR THEIR RECEPTION AND APPLICATION IN THERAPY
EA199900608A1 (en) NEW PHARNESILTRANSFERASE INHIBITORS, METHODS FOR THEIR PRODUCTION, CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE PRODUCTION OF MEDICUMENTS
TR200103286T2 (en) Cyclocarbamate derivatives as progesterone receptor modulators
SE8306764L (en) NEW ETHENDIAMIN AND GUANIDINE DERIVATIVES
PT90097A (en) PROCESS FOR THE PREPARATION OF NEW 5,7-DIHYDRO-PYRROLE (3,2-F) BENZOXAZOL-6-ONES SUBSTITUTED BY HETEROCYCLIC SUBSTITUTS, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure